Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that its "NASAR" clinical trial with its BentrioTM nasal
Company progressing with plans to focus on its RNA business
Advancing discussions for divestiture or spin-off of legacy assets, including BentrioTM and AM-125 nasal sprays
Bentrio revenues were $1.3